Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 09, 2023 07:05 ET | Source: Helius Medical Technologies, Inc.

Helius Medical Technologies Announces Authorization from Health Canada to Market Portable Neuromodulation Stimulator (PoNS®) Device for the Treatment of Gait Deficit Due to Mild and Moderate Symptoms from Stroke

NEWTOWN, Pa., March 09, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach...
March 06, 2023 07:30 ET | Source: Helius Medical Technologies, Inc.

Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

NEWTOWN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
March 02, 2023 16:05 ET | Source: Helius Medical Technologies, Inc.

Helius Medical Technologies to Present at the 35th Annual ROTH Conference

NEWTOWN, Pa., March 02, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
February 15, 2023 07:05 ET | Source: Helius Medical Technologies, Inc.

Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting

NEWTOWN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and...
January 23, 2023 07:05 ET | Source: Helius Medical Technologies, Inc.

Helius Medical Technologies, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2022

-- Q4 2022 revenue projected to range from $275,000 to $285,000 ---- Full year 2022 revenue projected to range from $780,000 to $790,000 ---- Unaudited year end cash balance of $14.5 million -- ...
January 19, 2023 09:00 ET | Source: Helius Medical Technologies, Inc.

Helius Medical Technologies to Present at the Virtual Q1 Investor Summit Microcap Event, January 26, 2023

NEWTOWN, Pa., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced...
January 10, 2023 07:05 ET | Source: Helius Medical Technologies, Inc.

Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program

-- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’ adherence to PoNS® therapy for gait...
January 05, 2023 07:41 ET | Source: Helius Medical Technologies, Inc.

Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis

NEWTOWN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) today announced the extension of a program that puts the company’s Portable Neuromodulation Stimulator...
January 03, 2023 07:05 ET | Source: Helius Medical Technologies, Inc.

Helius Launches UpScript Telehealth e-Commerce Site, Making it Easier for Americans with Multiple Sclerosis to Access Neurotech that can Improve their Ability to Walk

NEWTOWN, Pa., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) launched a new e-commerce site that makes it easier for Americans experiencing issues with their gait to...
December 30, 2022 16:05 ET | Source: Helius Medical Technologies, Inc.

Helius Medical Technologies, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

NEWTOWN, Pa., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced...